A Single-Arm Investigator-Initiated Tria (IIT) Evaluating the Safety and Preliminary Efficacy of Autologous Drug-Loaded Neutrophils (NeuMed) in Patients With Unresectable Pancreatic Cancer

The goal of this clinical trial is to learn if Autologous Drug-Loaded Neutrophils (NeuMed) can treat patients with Unresectable Pancreatic Cancer. The drug carried by the Autologous Neutrophils is Monomethyl Auristatin E. The main questions it aims to answer are: First, to verify the safety of Autologous Drug-Loaded Neutrophils (NeuMed) in patients with Unresectable Pancreatic Cancer. Second, to assess the anti-tumor efficacy of Autologous Drug-Loaded Neutrophils (NeuMed) in patients with Unresectable Pancreatic Cancer.

Trial Details

NCT ID
NCT07198659
Phase
EARLY_PHASE1
Sponsor
The First Affiliated Hospital of Air Force Medicial University
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Monomethyl Auristatin E (MMAE) / autologous neutrophil biological agents
Locations (sample)
  • Xi’an, Shanxi, China|35.99785,113.52486

Key Eligibility Criteria

  • 18-70 years
  • Obtain an informed consent form voluntarily signed by the patient themselves
  • patients with Unresectable Pancreatic Cancer confirmed by Histopathology
  • Patients who either: 1) have received standard first-line treatments, proven ineffective or causing intolerable adverse effects; or 2) have not rec…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →